IMV Inc. · OTC:IMVIF
IMV — Immunovaccine — Investor Presentation (February 2015)
25 slides from IMV's investor presentation, February 2015
Slide 1: Immunovaccine Inc.
February 2015 Immunovaccine Inc. (TSX: IMV) Strong, Fast and Long Lasting Vaccines for Cancer and Infectious Diseases
Slide 2: Disclaimer
DISCLAIMER This documentation is a presentation of general background information about Immunovaccine’s activities, current as of the date of the presentation. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or pote
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are based on the estimates a
Slide 4: Core Vaccine Technology - DepoVax
CORE VACCINE TECHNOLOGY- DEPOVAX™ • A differentiated vaccine formulation technology • Enables powerful cancer and infectious disease vaccines • Currently in phase 2 clinical trials in cancer with lead cancer vaccine DPX-Survivac • Entering a phase 1 study for an infectious disease vaccine against Re
Slide 5: Strategic Goals
STRATEGIC GOALS • Immuno-oncology – Execute open label phase 2 trial with DPX-Survivac in Lymphoma, initial data expected in 2015 – Establish a combination immunotherapy clinical collaboration with a partner • Infectious diseases – Establish the safety and activity of DPX-RSV in a phase 1 study in 2
Slide 6: Advantages of the DepoVax Technology
ADVANTAGES OF THE DEPOVAX™ TECHNOLOGY • An oil based formulation forcing prolonged vaccine processing by the immune system • Mature technology with scalable GMP manufacturing process • Dry format provides prolonged product shelf life Vaccine is injected subcutaneously or intra-muscularly 6 Immunovac
Slide 7: Immunovaccine's Pipeline Based on DepoVax
IMMUNOVACCINE’S PIPELINE BASED ON DEPOVAX™ Company sponsored programs Collaborations *clinical trial planned 7 Immunovaccine Proprietary Information
Slide 8: The Promise of Immunotherapy
THE PROMISE OF IMMUNOTHERAPY Immunotherapies to become the backbone of more than 60% of cancer treatments (Andrew Baum, Citigroup) 8 Immunovaccine Proprietary Information
Slide 9: Pharma and Investor Interest in Immunotherapy
PHARMA AND INVESTOR INTEREST IN IMMUNOTHERAPY Company Announcement AZ/ Medimmune August 23, 2013: Acquires Amplimmune (anti-PD-1) for $225M + up to $275M GSK June 1, 2014: Enters deal with Adaptimmune for developing engineered autologous T cells therapies, up to $350M Pfizer June 18, 2014: Enters de
Slide 10: Combination Immunotherapy - A New Paradigm for Cancer Therapy
COMBINATION IMMUNOTHERAPY- A NEW PARADIGM FOR CANCER THERAPY Company Announcement BMS/BMS Combination of anti PD-1 and anti-CTLA-4 showed a marked increase in response rate in melanoma AZ/ Advaxis AZ/ Medimmune collaborates with Advaxis for combination of anti- PDL-1 and a Listeria based vaccine for
Slide 11: Survivin – A Validated Target for a Cancer Vaccine
SURVIVIN – A VALIDATED TARGET FOR A CANCER VACCINE • Broadly applicable for solid tumors and hematological cancers • Plays an important role in the control of apoptosis, cell division and metastasis • A prognostic factor associated with cancer progression • A cancer stem cell antigen (150 scientific
Slide 12: Broad Utility of a Survivin Vaccine in Solid Tumor and Blood Cancers
BROAD UTILITY OF A SURVIVIN VACCINE IN SOLID TUMOR AND BLOOD CANCERS % of patients Indication expressing Reference survivin Ovarian Cancer 90 Vermeij et al, Clin and Dev Immunology, 2010 Breast Cancer 90 Yakirevich et al, Human Pathol, 2011 Melanoma 90 Takeuchi et al, Int J. Cancer, 2005 Lung Cancer
Slide 13: DPX-Survivac Therapy Activates Robust T Cells in Ovarian Cancer Patients
DPX-SURVIVAC THERAPY ACTIVATES ROBUST T CELLS IN OVARIAN CANCER PATIENTS Rapid, strong and durable T cells induced Vaccine schedule Vaccine schedule Phase 1 Phase 1b 13 Immunovaccine Proprietary Information
Slide 14: Clinical Activity of DPX-Survivac Therapy in Ovarian Cancer
CLINICAL ACTIVITY OF DPX-SURVIVAC THERAPY IN OVARIAN CANCER Patient with stable tumor and rising CA-125 experienced a 43% reduction in tumor size and a drop in CA-125 following vaccination Immune CA-125 response level 9 Sep 2013 5 Nov 5.61 cm Dec 2013 2013 4.45 cm Feb 2014 4.00 3.15 cm May 2014 3.30
Slide 15: Clinical Strategy for DPX-Survivac Combination Therapy
CLINICAL STRATEGY FOR DPX-SURVIVAC COMBINATION THERAPY Patient Profile Therapy (A) No Evidence of DPX-Survivac Disease or A+B Activation of T cells Minimal Residual Disease Effective Cancer (C) Therapy (B) Checkpoint Immune Measurable A+B+C Inhibitors Modulators disease Reduced Suppression Amplifica
Slide 16: Combination of Vaccine and Checkpoint Blockade Provides Enhanced Anti-Tumor Activity
COMBINATION OF VACCINE AND CHECKPOINT BLOCKADE PROVIDES ENHANCED ANTI-TUMOR ACTIVITY Combination strategy provides effective control of aggressive tumors C3 Tumor Challenge 1500 Cyclophosphamide mCPA, anti-PD1 + anti PD1 Tumor Volume (mm ) 3 Cyclophosphamide mCPA, + vaccine vaccine, isotype 1000 mCP
Slide 17: DPX-Survivac Upcoming Clinical Trials
DPX-SURVIVAC UPCOMING CLINICAL TRIALS • Open label phase 2 in Lymphoma (company sponsored) – Enrolling up to 24 patients with recurrent DLBCL – Primary objective is to determine the objective response rate (ORR) – Designed with ability to amend the trial to include a checkpoint inhibitor • Randomize
Slide 18: DepoVax Enabling Multiple Infectious Disease Opportunities
DEPOVAX ENABLING MULTIPLE INFECTIOUS DISEASE OPPORTUNITIES • DPX-RSV (company controlled) – A preventative vaccine for respiratory syncytial virus – Initially targeting the elderly population – Entering a phase 1 study in older healthy volunteers (50-64 yrs) • DPX- Anthrax (collaboration with the NI
Slide 19: A Novel RSV Vaccine Targeting the Small Hydrophobic Ectodomain
A NOVEL RSV VACCINE TARGETING THE SMALL HYDROPHOBIC ECTODOMAIN • RSV causes severe Small hydrophobic protein (SH) respiratory illness • Affects the elderly and young children • There is currently no vaccine • IMV initially developing DPX- RSV for the elderly • Phase 1 trial to establish safety and a
Slide 20: Anthrax Vaccine Opportunity
ANTHRAX VACCINE OPPORTUNITY • A bacterial Infection that attacks major organs and is deadly • Anthrax spores can be weaponized • Anthrax vaccine is an important component of the Strategic National Stockpile (SNS) of the US • Substantial Investment by the US government committed for developing better
Slide 21: Potential Upcoming Milestones
POTENTIAL UPCOMING MILESTONES Milestone Expected Date Initiation of Phase II DPX-Survivac Lymphoma Study Q1 2015 Data from Second NIH Ebola Challenge Study (non human primates) Q1 2015 Initiation of Phase I DPX-RSV Study H1 2015 Initial Data from Phase I DPX-RSV Trial H2 2015 Initial Data from Phase
Slide 22: Immunovaccine (TSX: IMV) Today (Feb 4, 2015)
IMMUNOVACCINE (TSX: IMV) TODAY (FEB 4, 2015) Share price $0.74 52 week range $0.30 - $1.50 Market cap $67.9M Shares outstanding 91.7M Avg. volume 395,000 Insider’s (approx) 25% Stock options & 10.73M warrants outstanding (share weighted-average exercise (as at December 31, 2014) price of $0.81) 22 I
Slide 23: Publicly Traded Biotech Companies with Cancer Vaccine Programs
PUBLICLY TRADED BIOTECH COMPANIES WITH CANCER VACCINE PROGRAMS Company Market Cap ($M) Vaccines Indication (Phase) February 4, 2015 Immunovaccine DPX-Survivac, Ovarian (Phase 1-2) 68* TSX: IMV DPX-0907 GBM (Phase 1-2) Galena Biopharma, Inc Nelipepimut-s (NeuVax) Breast Cancer (Phase 3) NASDAQ:GALE 1
Slide 24: IMV Leadership & Board
IMV LEADERSHIP & BOARD • Leadership team: – Marc Mansour, Ph.D., MBA, Chief Executive Officer & Board Member – Kimberly Stephens, CA, Chief Financial Officer – Neil Berinstein, M.D., Medical Affairs Advisor – Irene Clement, Regulatory Affairs Advisor • Board Members: – Albert Scardino • Chairman – J
Slide 25: Immunovaccine Inc. (TSX: IMV)
IMMUNOVACCINE INC. (TSX: IMV) For more information: Marc Mansour, Ph.D., MBA Chief Executive Officer T: 902-421-5735 ext. 3 E: [email protected] www.imvaccine.com
Immunovaccine — Investor Presentation (February 2015) on 6ix